Scroll

alitretinoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
retinol derivatives	3862	5300-03-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alitretinoin panrexin panretyn panretin 9-cis-retinoic acid	A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. Molecular weight: 300.44 Formula: C20H28O2 CLOGP: 6.74 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -4.80 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alitretinoin
panrexin
panretyn
panretin
9-cis-retinoic acid

A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA.

Molecular weight: 300.44
Formula: C20H28O2
CLOGP: 6.74
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -4.80
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.33 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 1 of 1 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 2, 1999	FDA	EISAI INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diverticulum oesophageal	54.45	48.51	7	450	144	63488421
Mandibular mass	53.14	48.51	7	450	175	63488390

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diverticulum oesophageal	54.61	51.57	7	506	158	79743717
Mandibular mass	52.53	51.57	7	506	215	79743660

Showing 1 to 2 of 2 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	D11AH04	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids
ATC	L01XF02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Retinoids for cancer treatment
CHEBI has role	CHEBI:25212	metabolites
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50176	keratolytic drugs
CHEBI has role	CHEBI:63794	retinoid X receptor agonists
FDA CS	M0018962	Retinoids
FDA EPC	N0000175607	Retinoid
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D003879	Dermatologic Agents

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID
Kaposi's Sarcoma Skin Lesions	indication
Mycosis fungoides	contraindication	118618005
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.17	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Retinoic acid receptor alpha	Nuclear hormone receptor	P10276	RARA_HUMAN	AGONIST	EC50	6.52	WOMBAT-PK	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN	AGONIST	EC50	6.50	WOMBAT-PK	CHEMBL
Retinoic acid receptor RXR-beta	Nuclear hormone receptor	P28702	RXRB_HUMAN	AGONIST	EC50	6.70	WOMBAT-PK	CHEMBL
Retinoic acid receptor RXR-gamma	Nuclear hormone receptor	P48443	RXRG_HUMAN	AGONIST	EC50	6.66	WOMBAT-PK	CHEMBL
Retinoic acid receptor beta	Nuclear hormone receptor	P10826	RARB_HUMAN	AGONIST	EC50	7.30	WOMBAT-PK	CHEMBL
Retinoic acid receptor gamma	Nuclear hormone receptor	P13631	RARG_HUMAN	AGONIST	EC50	7.13	WOMBAT-PK	CHEMBL
Nuclear receptor ROR-gamma	Nuclear hormone receptor	P51449	RORG_HUMAN		EC50	4.85	CHEMBL
Nuclear receptor subfamily 4 group A member 1	Nuclear other	P22736	NR4A1_HUMAN		Kd	6.09	CHEMBL
Oxysterols receptor LXR-beta	Nuclear other	P55055	NR1H2_HUMAN		EC50	5.76	CHEMBL
Oxysterols receptor LXR-alpha	Nuclear other	Q13133	NR1H3_HUMAN		EC50	5.96	CHEMBL

Showing 1 to 10 of 17 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
007747	NDDF
116086005	SNOMEDCT_US
14093	MMSL
1UA8E65KDZ	UNII
219098	RXNORM
2645	IUPHAR_LIGAND_ID
4021155	VUID
4021155	VANDF
409488005	SNOMEDCT_US
449171	PUBCHEM_CID

Showing 1 to 10 of 20 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CLINDAMYCIN 1% / NIACINAMIDE 4% / TRETINOIN 0.05%	HUMAN PRESCRIPTION DRUG LABEL	3	72934-2054	CREAM	0.05 g	TOPICAL	unapproved drug other	4 sections
PANRETIN	Human Prescription Drug Label	1	59212-601	GEL	60 mg	TOPICAL	NDA	22 sections

Showing 1 to 2 of 2 entries

Previous1Next